Humira Buyers Say They've Proven AbbVie's 'Patent Thicket'
By Nadia Dreid · November 25, 2019, 9:31 PM EST
AbbVie shouldn't be able to escape first-of-its-kind litigation accusing the pharmaceutical giant of building a "patent thicket" around its immunosuppressant Humira in order to block cheaper biosimilars from coming onto the...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login